Sugi Predict

Sugi Predict / Compounds / SCHEMBL2389792

SCHEMBL2389792

SCHEMBL2389792

CCOC(=O)[C@H]1C[C@@H](O)CN1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 4/20 0.37
▸ DPP8 Q6V1X1 4/20 0.37
▸ DPP9 Q86TI2 4/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ SMYD3 Q9H7B4 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ PPM1B O75688 1/20 0.34
▸ PTPN1 P18031 1/20 0.34
▸ PPP1CC P36873 1/20 0.34
▸ FUCA1 P04066 2/20 0.34
▸ GLB1 P16278 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201847 1.00 DPP4 (0.37) DPP4DPP8DPP9KDM4ECYP1A2
SCHEMBL3316703 1.00 DPP4 (0.37) DPP4DPP8DPP9KDM4ECYP1A2
SCHEMBL1567974 1.00 DPP4 (0.37) DPP4DPP8DPP9KDM4ECYP1A2
SCHEMBL9684605 1.00 DPP4 (0.37) DPP4DPP8DPP9KDM4ECYP1A2
SCHEMBL4892915 1.00 DPP4 (0.37) DPP4DPP8DPP9KDM4ECYP1A2
SCHEMBL1470851 1.00 DPP4 (0.37) DPP4DPP8DPP9KDM4ECYP1A2
Hydrochloric Acid SCHEMBL7312757 0.98 KDM4E (0.38) DPP4DPP8DPP9KDM4ECYP1A2
Hydrochloric Acid SCHEMBL2705454 0.98 KDM4E (0.38) DPP4DPP8DPP9KDM4ECYP1A2
Hydrochloric Acid SCHEMBL132277 0.98 KDM4E (0.38) DPP4DPP8DPP9KDM4ECYP1A2
Hydrochloric Acid SCHEMBL7306465 0.98 KDM4E (0.38) DPP4DPP8DPP9KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518764-B2 Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-12-06 — — US disclosed
US-20200331921-A1 INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2020-10-22 — — US disclosed
WO-2019153080-A1 INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2019-08-15 — — WO disclosed
US-8012983-B2 Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-09-06 — — US disclosed
US-8012983-B2 Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-09-06 — — US disclosed
US-8012983-B2 Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-09-06 — — US disclosed
US-20090286798-A1 FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2009-11-19 — — US disclosed
US-20090286798-A1 FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2009-11-19 — — US disclosed
US-20090286798-A1 FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2009-11-19 — — US disclosed
WO-2008134035-A1 ALPHA-UNSUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-A] PYRIMIDINE AMIDE DERIVATIVES PANACOS PHARMACEUTICALS, INC. (US) 2008-11-06 — — WO disclosed
EP-1656133-A4 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2008-10-29 — — EP disclosed
US-7435831-B2 Bicyclic and bridged nitrogen heterocycles CHEMOCENTRYX, INC. (US) 2008-10-14 — — US disclosed
US-7435831-B2 Bicyclic and bridged nitrogen heterocycles CHEMOCENTRYX, INC. (US) 2008-10-14 — — US disclosed
US-7435830-B2 Bicyclic and bridged nitrogen heterocycles CHEMOCENTRYX, INC. (US) 2008-10-14 — — US disclosed
US-7435830-B2 Bicyclic and bridged nitrogen heterocycles CHEMOCENTRYX, INC. (US) 2008-10-14 — — US disclosed
US-20080027127-A1 Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use FAUST PHARMACEUTICALS (FR) 2008-01-31 — — US disclosed
US-20080027127-A1 Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use FAUST PHARMACEUTICALS (FR) 2008-01-31 — — US disclosed
EP-1656133-A2 MITOTIC KINESIN INHIBITORS Merck & Co., Inc. (US) 2006-05-17 — — EP disclosed
WO-2005118533-A1 TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE FAUST PHARMACEUTICALS (FR) 2005-12-15 — — WO disclosed
WO-2005017190-A2 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2005-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518764-B2 Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction BCL6, BCL6B, BCL3 DPP4 3473/4885DPP8 2374/4885DPP9 2864/4885
US-20200331921-A1 INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF BCL6, BCL6B, BCL3 DPP4 3489/4885DPP8 2465/4885DPP9 2760/4885
US-20090286798-A1 FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL1B, IL1A, PTGER1 DPP4 745/4885DPP8 1517/4885DPP9 2683/4885
US-20080027127-A1 Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use SUCNR1, GLRA1, CNR1 DPP4 3058/4885DPP8 2865/4885DPP9 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.